Rhythm Pharmaceuticals Inc. has presented its long-term growth strategy, highlighting key developments in recent clinical trials and product demand. The company reported strong results from the Phase 3 trial of setmelanotide in acquired hypothalamic obesity and is on track to complete U.S. and EU regulatory submissions in the third quarter of 2025. Additionally, there is solid patient demand growth for IMCIVREE® (setmelanotide) in the first quarter of 2025, with a data readout for the Phase 2 trial of oral bivamelagon in acquired hypothalamic obesity expected in the third quarter of 2025. The company remains well-capitalized, with an expected cash runway extending into 2027. You can access the full presentation through the link below.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。